ArticleMetabolites2021
Growth and Overall Health of Patients with
Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Citrate Transporter NaCT and Enamel Mineralization: TheInternational journal of molecular sciences · 2026Article
- AAV-mediated gene therapy in a model of SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes.The Journal of clinical investigation · 2026Article
- Modulation of NMDA receptor signaling and zinc chelation prevent seizure-like events in a zebrafish model of SLC13A5 epilepsy.PLoS biology · 2025Article
- Identification of a novel homozygousFrontiers in genetics · 2025Article
- Article
- Novel Approaches to Studying SLC13A5 Disease.Metabolites · 2024Review
- The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development.BMC medicine · 2023Article
- Targeting Longevity GeneMetabolites · 2023Article
- Mapping the Metabolic Niche of Citrate Metabolism andMetabolites · 2023Review
- Characterizing a rare neurogenetic disease, SLC13A5 citrate transporter disorder, utilizing clinical data in a cloud-based medical record collection system.Frontiers in genetics · 2023Article
- A specialized metabolic pathway partitions citrate in hydroxyapatite to impact mineralization of bones and teeth.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Review
- INDY-From Flies to Worms, Mice, Rats, Non-Human Primates, and Humans.Frontiers in aging · 2021Review
- The growing research toolbox for SLC13A5 citrate transporter disorder: a rare disease with animal models, cell lines, an ongoing Natural History Study and an engaged patient advocacy organization.Therapeutic advances in rare diseaseReview
- Linking Angelman and dup15q data for expanded research (LADDER) database: a model for advancing research, clinical guidance, and therapeutic development for rare conditions.Therapeutic advances in rare diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We were interested in elucidating the non-neurologic health of patients with autosomal recessive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.